Valneva (NASDAQ:VALN) Shares Gap Down on Analyst Downgrade

Valneva SE (NASDAQ:VALN - Get Free Report)'s share price gapped down prior to trading on Tuesday after Guggenheim lowered their price target on the stock from $17.00 to $15.00. The stock had previously closed at $7.43, but opened at $7.28. Guggenheim currently has a buy rating on the stock. Valneva shares last traded at $7.03, with a volume of 5,928 shares traded.

Separately, HC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Valneva in a research note on Friday, March 21st.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN lifted its holdings in Valneva SE (NASDAQ:VALN - Free Report) by 14.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Stock Performance

The business's fifty day moving average is $6.63 and its 200-day moving average is $5.61. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $589.95 million, a PE ratio of -55.85 and a beta of 1.93.

Remove Ads

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The business had revenue of $56.48 million during the quarter, compared to the consensus estimate of $55.64 million. As a group, research analysts predict that Valneva SE will post 0.13 EPS for the current fiscal year.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.